DeVeaugh-Geiss J, Landau P, Katz R
Psychopharmacol Bull. 1989;25(1):36-40.
Two multicenter, double-blind, placebo-controlled clinical trials were conducted to evaluate the effectiveness of 10 weeks of treatment with up to 300 mg daily of clomipramine in nondepressed patients with OCD. There were 575 patients enrolled in these clinical trials, and preliminary analyses of data from 384 of these patients demonstrate a virtual absence of placebo response, a very low rate of premature discontinuation, and for patients receiving clomipramine, a statistically and clinically significant improvement in OCD symptoms (40%-45% mean improvement with clomipramine vs. 4%-5% mean improvement with placebo). In general, clomipramine was well tolerated in doses of up to 300 mg daily.
开展了两项多中心、双盲、安慰剂对照临床试验，以评估每日高达300毫克氯米帕明治疗10周对无抑郁症状的强迫症患者的有效性。这些临床试验共纳入575例患者，对其中384例患者的数据进行的初步分析表明，几乎不存在安慰剂反应，过早停药率极低，对于接受氯米帕明治疗的患者，强迫症症状有统计学意义和临床意义上的显著改善（氯米帕明组平均改善40%-45%，安慰剂组平均改善4%-5%）。一般来说，每日剂量高达300毫克的氯米帕明耐受性良好。
